^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

INCB106385

i
Other names: INCB106385
Associations
Company:
Incyte
Drug class:
Adenosine A2A receptor antagonist, Adenosine A2B receptor antagonist
Associations
9ms
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors (clinicaltrials.gov)
P1, N=54, Completed, Incyte Corporation | Active, not recruiting --> Completed
Trial completion • Combination therapy • Metastases
|
CD8 (cluster of differentiation 8)
|
Zynyz (retifanlimab-dlwr) • INCB106385
11ms
Study of INCA 0186 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=57, Active, not recruiting, Incyte Corporation | Trial completion date: Jan 2024 --> Jun 2025 | Trial primary completion date: Jan 2024 --> Jun 2025
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
CD8 (cluster of differentiation 8)
|
Zynyz (retifanlimab-dlwr) • INCA00186 • INCB106385
over1year
Study of INCA 0186 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=57, Active, not recruiting, Incyte Corporation | Recruiting --> Active, not recruiting | N=210 --> 57 | Trial completion date: Feb 2025 --> Jan 2024 | Trial primary completion date: Feb 2025 --> Jan 2024
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
CD8 (cluster of differentiation 8)
|
Zynyz (retifanlimab-dlwr) • INCA00186 • INCB106385
over1year
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors (clinicaltrials.gov)
P1, N=54, Active, not recruiting, Incyte Corporation | Recruiting --> Active, not recruiting | N=230 --> 54
Enrollment closed • Enrollment change • Combination therapy • IO biomarker • Metastases
|
CD8 (cluster of differentiation 8)
|
Zynyz (retifanlimab-dlwr) • INCB106385
2years
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors (clinicaltrials.gov)
P1, N=230, Recruiting, Incyte Corporation | Trial completion date: Apr 2024 --> Dec 2023 | Trial primary completion date: Apr 2024 --> Dec 2023
Trial completion date • Trial primary completion date • Combination therapy • IO biomarker • Metastases
|
CD8 (cluster of differentiation 8)
|
Zynyz (retifanlimab-dlwr) • INCB106385
2years
Study of INCA 0186 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=210, Recruiting, Incyte Corporation | Trial completion date: Aug 2024 --> Jan 2025 | Trial primary completion date: Aug 2024 --> Jan 2025
Trial completion date • Trial primary completion date • Combination therapy
|
CD8 (cluster of differentiation 8)
|
Zynyz (retifanlimab-dlwr) • INCA00186 • INCB106385
almost3years
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors (clinicaltrials.gov)
P1, N=238, Recruiting, Incyte Corporation | Trial completion date: Dec 2023 --> Apr 2024 | Trial primary completion date: Dec 2023 --> Apr 2024
Trial completion date • Trial primary completion date • Combination therapy • IO biomarker
|
CD8 (cluster of differentiation 8)
|
Zynyz (retifanlimab-dlwr) • INCB106385
almost3years
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors (clinicaltrials.gov)
P1, N=238, Recruiting, Incyte Corporation | Trial completion date: May 2024 --> Dec 2023
Trial completion date • Combination therapy • IO biomarker
|
CD8 (cluster of differentiation 8)
|
Zynyz (retifanlimab-dlwr) • INCB106385
almost3years
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors (clinicaltrials.gov)
P1, N=238, Recruiting, Incyte Corporation | Trial completion date: Jul 2023 --> May 2024 | Trial primary completion date: Jul 2023 --> Dec 2023
Trial completion date • Trial primary completion date • Combination therapy • IO biomarker
|
CD8 (cluster of differentiation 8)
|
Zynyz (retifanlimab-dlwr) • INCB106385
3years
Study of INCA 0186 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=230, Recruiting, Incyte Corporation | Not yet recruiting --> Recruiting
Clinical • Enrollment open • Combination therapy
|
CD8 (cluster of differentiation 8) • CD73 (5'-Nucleotidase Ecto)
|
Zynyz (retifanlimab-dlwr) • INCA00186 • INCB106385
over3years
Clinical • New P1 trial • Combination therapy
|
CD8 (cluster of differentiation 8) • CD73 (5'-Nucleotidase Ecto)
|
Zynyz (retifanlimab-dlwr) • INCA00186 • INCB106385
over3years
[VIRTUAL] Discovery and preclinical characterization of INCA00186, a humanized monoclonal antibody antagonist of CD73, as a cancer immunotherapy (AACR 2021)
In summary, the data presented in this study demonstrates that INCA00186 is a potent CD73 antagonist and effectively attenuates adenosine induced immunosuppression in the tumor microenvironment. INCA00186 demonstrated anti-tumor immunity alone and, to a greater extent, in combination with the A2A/A2B adenosine receptor antagonist INCB106385.
Preclinical • Late-breaking abstract
|
IFNG (Interferon, gamma) • CD73 (5'-Nucleotidase Ecto) • CD34 (CD34 molecule) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)
|
INCA00186 • INCB106385